How much funding has STÄMM raised?

STÄMM has raised $17.0M in total funding, most recently a Series A round.

Who are STÄMM's investors?

STÄMM's investors include Varana Capital, Draper Associates, Vista Equity Partners, SOSV.

Where is STÄMM headquartered?

STÄMM is headquartered in Switzerland.

STÄMM

Biomanufacturing everywhere

Switzerland · Founded 2013 · $17.0M raised

Biotech

Founded: 2013
Business Model: B2B
Website: stamm.bio

Total Funding: $17.0M
Last Round: $17.0M Series AFeb 2022
Rounds: 1

About

Stämm is an advanced biomanufacturing company developing high-throughput bioprocessing solutions for biologics and cell therapy production. The company combines bioengineering, Bio AI, and continuous bioreactor technology to accelerate cell line development for clinical and commercial manufacturing. Its proprietary continuous bioreactor has been shown to increase antibody productivity by up to 30x in European and American pilots. Stämm also builds AI-powered computational platforms that model cell biomolecular behavior to accelerate wetlab bio-innovation cycles.

Summary

STÄMM is a Biotech company based in Switzerland, founded in 2013. It has raised $17.0M in total across 1 round, most recently a $17.0M Series A round in Feb 2022. Investors include Varana Capital, Draper Associates and Vista Equity Partners.